Tissue Factor Expression in Stage C Heart Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

1996-12-31

Study Completion Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Monocyte tissue factor (TF) was characterized in Class C heart failure (HF) vs. 25 age-matched volunteers. TF was 2.9 fold higher (p \< 0.001) in HF patients vs. controls. HF patients showed increased clinical events (RR=1.29, p=0.04) when comparing procoagulant activity above/below median. HF is associated with increased TF expression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hepatocyte Growth Factor (HGF) Concentration in Myocardial Infarction

NCT01233336

Acute Coronary Syndrome Myocardial Infarction

COMPLETED

LYmphangiogenesis FacTors in Heart Failure States

NCT03141567

Heart Failure Heart Failure With Reduced Ejection Fraction Heart Failure With Normal Ejection Fraction

COMPLETED

The Relationship Between Heart Function and Metabolism in HFpEF Patients

NCT05053256

Heart Failure With Preserved Ejection Fraction

UNKNOWN

Serum Catestatin Expression and Cardiometabolic Parameters in Patients With Congestive Heart Failure

NCT03389386

Heart Failure，Congestive

COMPLETED

Strain X Cardiopulmonary Test

NCT02869178

Heart Failure

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Monocyte tissue factor (TF) was characterized in Class C heart failure (HF) vs. 25 age-matched volunteers. TF was 2.9 fold higher (p \< 0.001) in HF patients vs. controls. HF patients showed increased clinical events (RR=1.29, p=0.04) when comparing procoagulant activity above/below median. HF is associated with increased TF expression.

Previous studies suggest that markers of coagulation are elevated in heart failure (HF). Tissue factor (TF) plays the cardinal role in initiating the coagulation cascade. This study determines TF expression in HF and its association with disease progression.

Methods: Monocytes were obtained from 50 NYHA function class II-IV HF patients and 25 age-matched disease-free volunteers. TF protein, TF procoagulant activity, and tissue factor pathway inhibitor (TFPI) were determined.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Age-Matched Healthy Controls

No interventions assigned to this group

Heart Failure

Subjects with LVEF \< 40%

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Heart failure subjects with symptomatic heart failure (New York Heart Association \[NYHA\] functional class II to IV) due to either idiopathic dilated cardiomyopathy or ischemic cardiomyopathy and had a left ventricular ejection fraction \< 0.35.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes